References
- Spreadborough MJ . Plasma microsampling, have we already reached the horizon? Presented at: 5th European Bioanalytical Forum Open Meeting. Barcelona, Spain, 14–16 November 2012.
- Jonsson O , Pama Villar R, Nilsson LBet al. Capillary microsampling of 25 µl blood for the determination of toxicokinetic parameters in regulatory studies in animals. Bioanalysis4(6), 661–674 (2012).
- Patel P , MullaH, TannaS, PandyaH. Failitating pharmacokinetic studies in children: a new use of dried blood spots. Arch. Dis. Child. 95, 484–487 (2010).
- O’Mara M , Huson-CurtisB, OlsonKet al. The effect of hematocrit and punch location on assay bias during quantitative bioanalysis of dried blood spot samples. Bioanalysis3(20), 2335–2347 (2011).
- Xu Y , WoolfEJ, AgrawalNGet al. Merck’s perspective on the implementation of dried blood spot technology in clinical drug development – why, when and how. Bioanalysis5(3), 351–350 (2013).
- Jonsson O , Pama Villar R, Nilsson LBet al. Validation of a bioanalytical method using capillary microsampling of 8 µl plasma samples: application to a toxicokinetic study in mice. Bioanalysis4(16), 1989–1998 (2012).
- Timmerman P , WhiteS, GlobigSet al. EBF and dried blood spots: from recommendations to potential resolution. Bioanalysis3(16), 1787–1789 (2011).
- Nilsson LB , AhnoffM, JonssonO. Capillary microsampling in the regulatory environment: validation and use of bioanalytical capillary microsampling methods. Bioanalysis5(6), 731–738 (2013).
Websites
- US FDA Guidence for Industry. Bioanalytical Method Validation. www.fda.gov/downloads/Drugs/./Guidances/ucm070107.pdf
- European Medicines Agency. Guideline on bioanalytical method validation. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf